Skip to main content
    K

    Kala Pharmaceuticals Inc (KALA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.56
    +3.42 (+2464.84%)

    Market Cap: $89,480

    Last updated: Nov 17, 2026 at 10:57 AM ET

    Kala Pharmaceuticals Inc (KALA) Financials: Revenue, Profit and Cash Flow

    Updated Aug 19, 2026. Financial statements from company filings, amounts in US dollars.

    Kala Pharmaceuticals reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$26.98M, operating cash flow was -$31.99M and free cash flow was -$32.01M. The quarter ended Jun 30, 2026 had revenue of $0 and net income of -$1.58M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $39.16M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0-100.0%N/AN/AN/A
    Dec 2022$3.89M-65.4%34.2%-2099.3%-1151.6%
    Dec 2021$11.24M+76.7%63.5%-1158.8%-1268.7%
    Dec 2020$6.36M+4.7%50.1%-1512.6%-1639.8%
    Dec 2019$6.07MN/A66.9%-1452.5%-1553.3%
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Jun 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$0$0$0$3.89M$11.24M$6.36M$6.07M$0$0$0
    Cost of revenue$0$0$0$2.56M$4.10M$3.17M$2.01M$0$0$0
    Gross profit$0$0$0$1.33M$7.14M$3.19M$4.07M$0$0$0
    Research and development$18.78M$22.09M$18.59M$17.65M$38.13M$18.35M$27.27M$29.29M$29.01M$25.03M
    Operating income-$39.16M-$40.98M-$39.66M-$81.71M-$130.25M-$96.23M-$88.22M-$64.72M-$39.88M-$32.67M
    Net income-$26.98M-$38.51M-$42.20M-$44.82M-$142.60M-$104.33M-$94.35M-$66.74M-$42.21M-$33.17M
    EBITDA-$30.99M-$33.28M-$37.54M-$33.67M-$126.44M-$94.27M-$86.42M-$64.09MN/A-$32.14M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Revenue$0$0$0$0$0$0$254.00K$0$0$0$70.00K$0
    Gross profit$0$0N/A$0$0$0-$69.00K$0$0$0-$70.00K$0
    Operating income-$1.72M-$1.80M-$10.22M-$7.24M-$11.03M-$10.67M-$9.46M-$9.99M-$9.61M-$11.93M-$9.62M-$8.76M
    Net income-$1.58M-$1.62M$686.00K-$7.56M-$11.15M-$11.30M-$8.18M-$8.95M-$9.58M-$11.81M-$8.63M-$8.70M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents of $7.56M were 79.7% of total assets of $9.49M, against total liabilities of $2.49M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$9.49M$55.48M$55.95M$86.82M$139.43M$221.61M$154.32M$220.97M$116.55M$46.33M
    Current assets$9.49M$52.80M$52.87M$85.94M$124.37M$171.38M$105.48M$177.03M$115.21M$45.63M
    Cash and equivalents$7.56M$51.18M$50.90M$70.50M$92.14M$77.26M$85.45M$170.90M$114.56M$45.47M
    Total liabilities$2.49M$43.15M$48.45M$67.85M$122.62M$121.61M$124.63M$115.99M$26.87M$15.70M
    Short-term debtN/A$10.34M$0$9.15M$3.82M$0$2.65M$926.00K$6.67M$556.00K
    Long-term debtN/A$20.10M$34.19M$37.94M$78.93M$72.24M$71.18M$70.23M$11.99M$9.10M
    Shareholder equity$7.00M$12.33M$7.50M$18.97M$16.80M$100.00M$29.69M$104.98M$89.68M-$87.76M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$10.58M$12.32M$9.49M$25.02M$36.05M$48.25M$55.48M$54.08M$61.61M$53.03M$55.95M$61.12M
    Total liabilities$1.54M$1.56M$2.49M$33.69M$39.26M$42.54M$43.15M$47.22M$47.89M$46.37M$48.45M$49.90M
    Cash and equivalents$229.00K$1.76M$7.56M$21.10M$31.94M$42.22M$51.18M$49.20M$54.20M$48.48M$50.90M$56.06M
    Shareholder equity$9.04M$10.76M$7.00M-$8.66M-$3.21M$5.71M$12.33M$6.86M$13.72M$6.66M$7.50M$11.22M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$31.99M-$29.38M-$27.93M-$78.91M-$108.23M-$90.69M-$92.72M-$54.12M-$34.10M-$27.35M
    Capital expenditures$15.00K$208.00K$610.00K$313.00K$886.00K$1.94M$1.33M$1.58M$480.00K$153.00K
    Free cash flow-$32.01M-$29.59M-$28.54M-$79.22M-$109.12M-$92.64M-$94.06M-$55.70M-$34.58M-$27.50M
    Dividends paidN/AN/A$365.00KN/AN/AN/AN/AN/A$0N/A
    Share repurchasesN/AN/AN/AN/AN/AN/AN/AN/AN/A$283.00K
    Investing cash flow-$15.00K-$208.00K-$429.00K$62.72M$70.80M-$78.21M-$1.33M-$1.58M-$480.00K-$153.00K
    Financing cash flow-$11.62M$29.88M$8.51M-$7.94M$42.55M$160.63M$8.98M$124.10M$103.70M$67.21M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$1.53M-$2.90M-$4.56M-$10.88M-$7.73M-$8.82M-$4.60M-$4.72M-$9.21M-$10.84M-$7.70M-$2.95M
    Capital expendituresN/A$16.00K$0$1.00K$16.00K$0$69.00K$90.00K$36.00K$13.00K$7.00K$281.00K
    Free cash flowN/A-$2.91M-$4.56M-$10.88M-$7.75M-$8.82M-$4.67M-$4.82M-$9.25M-$10.86M-$7.70M-$3.23M
    Last 12 quarters

    Frequently Asked Questions About KALA

    What is Kala Pharmaceuticals' annual revenue?

    Kala Pharmaceuticals reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Kala Pharmaceuticals profitable?

    No. Kala Pharmaceuticals reported net income of -$26.98M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does KALA generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$31.99M minus capital expenditures of $15.00K produced free cash flow of -$32.01M.

    How much debt does Kala Pharmaceuticals have?

    The balance sheet dated Dec 31, 2025 reported cash and equivalents of $7.56M.